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Background: Patients with single hepatocellular carcinoma (HCC) usually undergo transarterial chemoembolization
(TACE) if they are not candidates for curative surgical or ablative therapy. The primary aim of the study was to
assess the overall survival and clinical determinants of survival in patients with single HCC who underwent TACE.
The secondary aims were tumor response, local and distant recurrence rates, time to recurrence and the impact of
TACE on liver function.
Methods: The outcomes of 148 consecutive patients with single HCC who underwent TACE from January 2004 to
December 2009 were retrospectively analyzed.
Results: Complete response (CR) was observed in 95/148 (64%) patients and a partial response (PR) in 39 (26%) patients.
The recurrence rate was 27%, 42% and 65% at 6, 12 and 24 months, respectively. The day after TACE, 56 (38%) patients
had a Child-Pugh increase ≥1 and 93 (63%) had a MELD increase ≥1. Median survival was 36.0 months with 1-, 3- and
5-year survival rates of 85%, 50% and 26%, respectively. Bland portal thrombosis was not seen to have any impact at
univariate survival analysis; however, a slight impairment of PS (PS-1) in small tumors had some, although minor, impact
on prognosis. Factors associated with shorter survival at multivariate analysis were tumor >5 cm, absence of CR, ascites,
alpha-fetoprotein (AFP) ≥14.5 ng/mL and a MELD increase ≥1.
Conclusions: Transarterial chemoembolization is a valid treatment option in patients with single HCC not suitable for
curative treatment. Bland PVT has no major impact on survival and a slight impairment of PS attributable to cirrhosis in
patients within the Milan criteria should not preclude the use of TACE.
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Curative treatment is considered the first choice treatment
for patients with single hepatocellular carcinoma (HCC)
according to the international guidelines [1]. In particular,
liver transplant (LT) is recommended in patients within
the Milan criteria (MC) [2], and surgical resection or
ablation in patients not suitable for LT [3]. In clinical
practice, however, patients with a single tumor unsuit-
able for curative treatment are usually treated with
transarterial chemoembolization (TACE) on the basis
of a clinical judgment. In fact, according to the “stage
migration” concept, patients who cannot receive the* Correspondence: fabio.piscaglia@unibo.it
1Division of Internal Medicine, Department of Digestive Disease and Internal
Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Via Albertoni
15, 40138 Bologna, Italy
Full list of author information is available at the end of the article
© 2014 Terzi et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.recommended treatment allocation within their stage
should be offered treatment with the next most suitable
option within the same stage or the next stage [1].
Transarterial chemoembolization is a well-established
treatment for HCC and the current guidelines recommend
TACE as a first line non-curative treatment for intermedi-
ate stage patients with multinodular asymptomatic tumors
without vascular invasion or extrahepatic spread [1]. None-
theless, the percentage of patients with single HCC who
routinely underwent TACE is higher than 40% in many
studies [4-6].
The primary endpoint of the present study was to
evaluate the overall survival and clinical determinants of
survival, including the presence of bland portal vein
thrombosis (PVT) and slight impairment of performance
status (PS), in patients with a single nodule of HCC whod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Flow chart of the study population.
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treatment.
The secondary end points were tumor response at
1 month, local and distant recurrence rates, time to recur-
rence and impact of TACE on liver function.
Patients and methods
Patient population
The present retrospective analysis was based on a data-
base of 902 consecutive patients who underwent TACE as
a first line treatment between January 2004 and December
2009 in the Interventional Radiology Unit of Sant’Orsola-
Malpighi Hospital in Bologna after a multidisciplinary
team (MDT) discussion. The analysis of the follow-up was
closed in May 2012 in order to have at least 30 months of
follow-up for each patient. The inclusion criteria for en-
rollment in the study was: (1) diagnosis of single HCC
according to the European Association for the Study of
the Liver/American Assoication for the Study of Liver
Diseases (EASL/AASLD) criteria [7,8]; (2) Child-Pugh-
Turcotte (CPT) hepatic function A or B; (3) PS 0 or 1
and (4) first conventional TACE performed between
January 2004 and December 2009. The exclusion criteria
were: (1) the absence of at least one imaging control (CT:
Computed Tomography and/or MRI: Magnetic Reson-
ance Imaging) before and after TACE treatment; (2) mul-
tiple HCC nodules; (3) portal branch/hepatic vein tumor
invasion or extrahepatic spread (4) Child-Pugh hepatic
function C; (5) PS ≥2; (6) previous treatment for HCC and
(7) non-conventional TACE treatment (DC-Beads, mixed
treatments or radioembolization).
Portal vein thrombosis was considered to be bland or
neoplastic based on definite criteria previously reported
by our group [9].
In the series of consecutive patients, one hundred and
forty-eight patients fulfilled the inclusion criteria, and were
therefore selected as the cohort for the study (Figure 1).
The study protocol complied with the provision of the
Good Clinical Practice guidelines and the Declaration of
Helsinki and was approved by the Institutional Review
Board S.Orsola-Malpighi hospital. Collection of informed
consents was waived given the retrospective nature of the
study.
Methods
TACE protocol and technical procedure
In our clinical practice, HCC treatment for patients with
single HCC follows the BCLC staging system [10] but
each case is discussed in MDT meetings and individually
tailored, according to the considerations recently included
in the recommendations of the Italian Association for the
Study of the Liver [11].
Transarterial chemoembolization treatment was per-
formed in single nodules if curative treatment was notfeasible due to tumor size, tumor location, technical ap-
plicability of treatment, severity of liver dysfunction, pres-
ence of portal hypertension, presence of comorbidities
and their severity, and individual consent for specific
treatment.
Before treatment, baseline clinical evaluation, laboratory
tests, chest X-ray and tumor stage were assessed in all pa-
tients. Very few patients underwent TACE despite a CPT
function of B8-B9, which usually contraindicates TACE
due to the risk of irreversible terminal liver failure. Those
patients were treated because they were on the waiting
list for liver transplantation and they could undergo sal-
vage liver transplantation in case of liver failure. At ad-
mission, daily living abilities were assessed and PS was
calculated [12]. According to the guidelines [1], all pa-
tients with compromised abilities (PS 1) were classified
as being into advanced tumor stage (BCLC-C) irre-
spective of their origin (given the extreme difficulty and
subjectivity to ascribe such complaints either to the
underlying cirrhosis or to the occurrence of cancer).
Conventional TACE was carried out by selective
catheterization of the hepatic arteries feeding the le-
sions; in the majority of patients, superselective or
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coaxial microcatheter (2.7-2.8 Fr Progreat™ Terumo or
Renegade™ Hi-flo Boston Scientific) passed through a
4Fr catheter previously placed in the hepatic artery. For
selective transarterial chemoembolization, the tip of the
microcatheter was placed into the hepatic arterial branch
afferent to the segment where the tumor was located. In
superselective TACE, the tip of the catheter was addition-
ally advanced into the sub-segmental branches feeding the
nodule [13]. A lobar technique was carried out in the case
of a nodule fed by multiple arteries or when the selective/
superselective catheterization of the feeding artery was
not technically feasible. All patients with PVT underwent
a selective/superselective procedure.
After microcatheter placement, a mixture of epirubicin
(Farmorubicin; Pfizer, Latina, Italy) and iodized oil
(Lipiodol; Guerbet, Milan, Italy) was injected under
fluoroscopic control, followed by embolization using
Spongel (Gelitaspongel®) particles until complete blockage
of the tumor-feeding vessels was demonstrated. When the
interventional radiologist was aware of being unable to
achieve complete tumor embolization in only a single
TACE session (for example, due to the use of the max-
imum dose of Epirubicin allowed), the treatment was split
into two sessions approximately 1 month apart. In the
present study, the two treatments were considered as only
one treatment cycle. The mean chemotherapeutic agent
dose administered per treatment was approximately 40 mg
of epirubicin (range, 20–75 mg) and the mean Lipiodol
dose administered was approximately 8 mL (range, 4–
15 mL). Upon demonstration of a persistent viable
tumor or intrahepatic distal recurrence at imaging
follow-up, TACE was repeated “on demand”.
Assessment of tumor radiological response and follow-up
Patients underwent imaging assessment (quadriphasic CT
or dynamic MRI) one month after TACE in order to
evaluate the radiological response according to clinical
practice. For the purpose of the study, all patients were
evaluated according to the modified Response Evaluation
Criteria in Solid Tumors (mRECIST) [14]. The response
was considered complete (CR) when a dense homogeneous
Lipiodol uptake with complete disappearance of any intra-
tumoral enhancement was observed in the target lesion at
CT scan or when no enhancement of the target nodule
was observed at Dynamic MRI [14]. The other radiological
responses were considered to be partial response (PR),
progressive disease (PD) and stable disease (SD) according
to the mRECIST criteria [14].
In all patients with a CR, a follow-up CT or MRI at 3–6
months was performed. A plain chest X-ray or chest CT
were additionally utilized in the follow-up. For the as-
sessment of overall survival, patient follow-up was car-
ried out at the closure time of the study, at the time ofdeath or at the last inpatient/outpatient clinical evaluation
when no additional information was available (patients
lost to follow-up). For the assessment of recurrence-free
survival, patients were checked at the time of recurrence
or death, at liver transplant (if performed) or at the last in-
patient/outpatient clinical evaluation when no additional
information was available (patients lost to follow-up).
Statistical analysis
Continuous variables were reported as medians and ranges.
Comparisons among groups were calculated using non-
parametric tests (Mann–Whitney and Wilcoxon). Categor-
ical variables were compared using the χ2 test. All tests
were considered significant at P <0.05. Overall survival was
defined as the time interval between TACE and death or
the date of the last follow-up. Univariate analysis was car-
ried out in order to identify the factors predicting survival.
Survival curves were computed according to Kaplan-Meier
methods and were compared using log rank tests. Variables
with P <0.1 in the univariate analysis were entered into a
stepwise Cox regression model (conditional backward se-
lection) to assess their impact as independent predictive
factors. For patients who dropped out of the study, survival
could be calculated by requesting the living status or time
of death from the registry offices of the patients’ home-
towns, making them assessable for the survival analysis.
Analysis of the data was carried out using SPSS statistical
analysis software (SPSS Inc., Chicago, Illinois, USA, 1999).
Results
Transarterial chemoembolization was the primary treat-
ment after diagnosis of HCC in 148 patients with a single
nodule of HCC who were not eligible for curative treatment
(final study group) (Figure 1); their characteristics are re-
ported in Tables 1 and 2. Transarterial chemoembolization
was performed once in 80 patients (54%), twice in 44 pa-
tients (30%), three times in 17 patients (11%) and 4
times in 7 patients (5%). All patients with hepatitis B virus
(HBV)-related cirrhosis received oral antiviral treatment
as appropriate.
Tumor response at 1 month
A CR at one month was obtained in 95/148 (64%) patients,
a PR in 39 (26%), SD in 1 patient and PD in 10 (7%). Three
patients were not evaluable (1 underwent radiofrequency
as a complementary treatment after TACE and 2 received
a liver transplant within 1 month after the procedure, be-
fore the CT).
At univariate analysis of pre-TACE clinical and tumoral
variables to predict a complete radiological response (CR
vs. non-CR), only tumor size was found to be a statistically
significant predictor of complete response (Table 3), in
particular, a tumor diameter ≤3 cm (P = 0.017) and, more
significantly, ≤5 cm (tumors within the Milan criteria,
Table 1 Baseline demographic, clinical and tumor




Gender male, n (%) 104 (70)
Age, median (years) (range) 64 (36–84)




Multiple etiologies 17 (12)
Unknown 12 (8)
Other 1 (1)
Lesion location, n (%)
Right lobe 110 (74)
Left lobe 38 (26)




Tumor size, median (cm) (range) 3.0 (0.8 – 15.0)
Milan criteria within, n (%)* 135 (91)
Portal vein thrombosis, n (%)
Absent 131 (88)
Segmental bland thrombosis 4 (3)
Lobar bland thrombosis 13 (9)
Serum AFP, median (ng/mL) (range) 14.5 (1.0 – 39576.0)
Ascites, n (%)
Absent 120 (81)
Slight – Moderate 23 (16)




Serum total bilirubin, median (mg/dL) (range) 1.34 (0.30 – 10.67)
Serum albumin, median (g/dL) (range) 3.60 (2.10 – 5.00)
Serum INR, median (range) 1.28 (1.00 – 1.97)
Hepatic function, n (%)
CPT-A 92 (62)
CPT-B 56 (38)
Performance status, n (%)
0 133 (90)
1 15 (10)
Table 1 Baseline demographic, clinical and tumor
characteristics of the whole patient cohort before TACE
treatment (Continued)





MELD score, median (range) 11 (6 – 24)
*patients with HCC ≤5 cm.
Abbreviations: HBV hepatits B virus, HCV hepatitis C virus, TACE transarterial
chemoembolization, AFP Alpha-fetoprotein, INR international normalized ratio,
CPT Child-Pugh-Turcotte score, BCLC Barcelona Clinic Liver Cancer, MELD Model
for end stage liver disease.
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alpha-fetoprotein (AFP) was found in incomplete
responders.
Local and distant recurrence after TACE
Out of 95 patients achieving a CR, 61 (64%) relapsed
after a median time of 9 months (range 2–72), 28 (30%)
did not relapse after a median follow-up of 13.5 months
(range 2–53) and 6 patients were not evaluable. Out of
the 61 patients who relapsed, 23 patients (38%) had local
relapse after a median of 10 months (range 2–37), 23
(38%) had distant intrahepatic relapse after a median of
8 months (range 2–72) and 15 (24%) had both local and
distant intrahepatic relapse after a median of 11 months
(range 3–36). No patient developed extrahepatic spread
before or concurrently with the detection of local or
intrahepatic relapse. The overall recurrence rate in pa-
tients with complete response was 27%, 42% and 65% at
6, 12 and 24 months, respectively.
Impact of TACE on laboratory tests the day after the
procedure
A significant negative impact on liver function was ob-
served the day after TACE treatment (Table 4). In particu-
lar, 56 (38%) patients suffered a CPT increase ≥1 point and
93 (63%) patients suffered a Model for end stage liver dis-
ease (MELD) score increase ≥1 point. Interestingly, a CPT
and a MELD score increase ≥1 were not related to a lobar
TACE procedure (P = 0.320 and P = 1.000, respectively).
The impact of TACE on the serum levels of albumin,
bilirubin, the international normalized ratio (INR), cre-
atinine and the MELD score the day after TACE is re-
ported in Figure 2. More in detail, the median serum
albumin values decreased from 3.60 mg/dL (range 2.10-
5.00) to 3.50 mg/dL (range 2.10–4.50; P < 0.001) whereas
the median serum values of bilirubin, the INR and the
MELD score increased from 1.34 mg/dL (range 0.30-
10.67), 1.28 (range 1.00-1.97) and 11 (range 6–24) to
1.84 mg/dL (range 0.30-13.94; P <0.001), 1.33 (range
Table 2 Clinical and tumor characteristics of the whole patient cohort before TACE treatment according to BCLC tumor
stage
Variable BCLC-0 (n = 16) BCLC-A (n = 104) BCLC-B (n = 13) BCLC-C (n = 15)
Within Milan Criteria, n (%)* 16 (100) 104 (100) 0 15 (100)
Tumor size, median (cm) (range) 1.3 (1.0 – 1.9) 3.0 (0.8 – 5.0) 6.0 (5.1 – 15.0) 3.0 (1.0 – 4.8)
Portal vein thrombosis, n (%)
Absent 14 (88) 94 (90) 11 (85) 12 (80)
Segmental bland thrombosis 0 3 (3) 0 1 (7)
Lobar bland thrombosis 2 (12) 7 (7) 2 (15) 2 (13)
Hepatic function pre TACE, n (%)
CPT-A 16 (100) 58 (56) 8 (62) 10 (67)
CPT-B 0 46 (44) 5 (38) 5 (33)
Performance status pre TACE, n (%)
0 16 (100) 104 (100) 13 (100) 0
1 0 0 0 15 (100)
Percentages should be read as columns.
*patients with HCC ≤5 cm.
Abbreviations: BCLC Barcelona Clinic Liver Cancer, TACE transarterial chemoembolization, CPT Child-Pugh-Turcotte score.
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spectively. The median serum value of creatinine increased
from 0.92 mg/dL (range 0.50-1.73) to 0.97 mg/dL
(0.57-2.27) but no statistical difference was observed
(P = 0.823).
Patients with a CPT score increase ≥1 point after the
first TACE underwent more often one single rather than
multiple TACE courses (70% vs 30% of cases respectively,
P = 0.006) in our routine clinical practice.
Overall patient survival after TACE
Out of the 148 patients who underwent TACE, 79 (53%)
died within the study period (January 2004 - May 2012)
and 4 patients were lost to follow-up. The median over-
all follow-up of the entire study population was 44.0 months
(95% CI = 33.5-54.5) with 1-, 3- and 5-year survival rates of
89%, 61% and 42%, respectively. If patients who underwent
liver transplant (who generally were long-term survivors)
were excluded (34 patients), the median overall follow-up
decreased to 36.0 months (95% CI = 24.6–47.4) with 1-year,
3-year and 5-year survival rates of 85%, 50% and 26%, re-
spectively. The median survival of patients within the Milan
criteria was 37 months, compared to 6 months of those be-
yond the Milan criteria.
At univariate analysis, tumor characteristics (and par-
ticularly tumor size), some liver function parameters and
the achievement of a complete radiological response
(Table 5) had a statistical impact on survival. Interestingly,
an increase of ≥1 point in the CPT or the MELD score the
day after TACE was significantly associated with lower sur-
vival (P = 0.003) (Table 4). On the opposite the number of
TACE was not associated with survival (P = 0.407). As
expected, median survival was also influenced by the
BCLC stage, but BCLC-B patients showed a lowermedian survival (6 months, P = 0.002) with respect to
BCLC 0-A (41 months) and BCLC-C (28 months) patients
(the latter categorized as BCLC-C only on the basis of PS-
1, but with tumor burden within the MC) (Figure 3). Fur-
thermore, the presence of bland segmental or lobar PVT
had no impact on overall survival but a slight impairment
in PS (PS-1) did have an impact on prognosis since sur-
vival in PS-1 patients (BCLC-C) was worse than in that of
PS-0 patients within the MC (BCLC 0-A). Nonetheless,
the impact of PS on survival was minor with respect to
the tumor burden since survival in PS-1 patients (BCLC-
C) was better than that in PS-0 patients beyond the MC
(BCLC-B) (Tables 5 and 6, Figure 3).
All the variables in the univariate analysis with P <0.1
(Table 5) were entered into a Cox regression analysis, ex-
cept for the CPT score and BCLC to avoid redundancy
since the variables upon which they are built were already
included in the analysis. After a conditional backward
selection, tumor diameter beyond the Milan criteria (P =
0.015, OR = 3.0), lack of a complete radiological tumor re-
sponse (P = 0.006, OR = 2.3), the presence of ascites before
TACE (P = 0.021, OR = 2.3), AFP ≥14.5 ng/mL (P = 0.007,
OR = 2.1) and a MELD score increase ≥1 point the day
after TACE (P = 0.037, OR = 2.0) remained significant in-
dependent predictors of a worse survival.
Discussion
Curative treatment is recommended as the first-line treat-
ment for patients with single HCC regardless of tumor
diameter [1,7]. In clinical practice, however, patients with
single tumors unfit for curative treatment are usually
treated by TACE, based on clinical judgment. According to
the current guidelines, TACE is the first line non-curative
treatment for intermediate stage patients [1]. No evidence
Table 3 Clinical and tumor characteristics of the whole patient cohort before TACE treatment according to tumor
response
Variable CR (n = 95) Non-CR (n = 50) P
Gender male, n (%) 0.122
Male 71 (70) 31 (30)
Female 24 (56) 19 (44)
Age, median (years) (range) 63 (36–83) 67.5 (45–84) 0.099
Cause of disease, n (%) 0.928
HBV 7 (50) 7 (50)
HCV 54 (66) 28 (34)
Alcohol 15 (79) 4 (21)
Multiple etiologies 9 (53) 8 (47)
Unknown 9 (75) 8 (25)
Other 1 (100) 3 (0)
Lesion location, n (%) 0.453
Right lobe 72 (67) 35 (33)
Left lobe 23 (61) 15 (39)
TACE selectivity, n (%) 0.992
Lobar 5 (50) 5 (50)
Selective 45 (63) 26 (37)
Superselective 45 (70) 19 (30)
Tumor size, n (cm) (%) 0.017
≤3.0 65 (73) 24 (27)
>3.0 30 (54) 26 (46)
Milan criteria, n (%) 0.004
Within (≤5.0 cm) 92 (69) 41 (31)
Beyond (>5.0 cm) 3 (25) 9 (75)
Portal vein thrombosis, n (%) 0.789
Absent 83 (65) 45 (35)
Bland thrombosis 12 (71) 5 (29)
Serum AFP, median (ng/mL) (range) 13.0 (1.0 – 10000.0) 21.0 (2.0 – 39576.0) 0.094
Ascites, n (%) 1.000
Absent 77 (66) 40 (34)
Present 18 (64) 10 (36)
Encephalopathy, n (%) 1.000
Absent 93 (66) 49 (34)
Slight 2 (67) 1 (33)
Serum total bilirubin, median (mg/dL) (range) 1.39 (0.30 – 7.56) 1.24 (0.35 – 7.72) 0.594
Serum albumin, median (g/dL) (range) 3.60 (2.10 – 5.00) 3.75 (2.40 – 4.90) 0.064
Serum INR, median (range) 1.29 (1.00 – 1.83) 1.23 (1.00 – 1.97) 0.365
Hepatic function, n (%) 0.155
CPT-A 55 (61) 35 (39)
CPT-B 40 (73) 15 (27)
Performance status, n (%) 0.775
0 86 (66) 44 (34)
1 9 (60) 6 (40)
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Table 3 Clinical and tumor characteristics of the whole patient cohort before TACE treatment according to tumor
response (Continued)
BCLC stage, n (%) 0.077
0 – A 83 (70) 35 (30)
B 3 (25) 9 (75)
C 9 (60) 6 (40)
MELD score, median (range) 12 (7 – 19) 11 (6 – 24) 0.637
Three patients not evaluable for tumor response were excluded from the analysis. Percentages should be read as rows.
Abbreviations: CR complete response, HBV hepatits B virus, HCV hepatitis C virus, TACE transarterial chemoembolization, AFP Alpha-fetoprotein, INR international
normalized ratio, CPT Child-Pugh-Turcotte score, BCLC Barcelona Clinic Liver Cancer, MELD Model for end stage liver disease.
“P<0.05 are reported as bold numbers”.
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is reported in the guidelines since the trials upon which
the guidelines are built [15], for the most part, included
patients with multiple nodules of HCC. Accordingly,
TACE is frequently performed outside the current treat-
ment guidelines in a considerable percentage of patients
with a single nodule, according to a “stage migration
strategy” [16].
Only a few studies have evaluated the efficacy of TACE
in patients with a single nodule [5,17,18] and a valid








Serum total bilirubin, median (mg/dL) (range) 1.34 (0.3
Serum albumin, median (g/dL) (range) 3.60 (2.1
Serum creatinine, median (range) 0.92 (0.5











Serum INR, median (range) 1.28 (1.0
MELD score, median (range) 11 (6
Percentages should be read as columns.
Abbreviations: CPT Child-Pugh-Turcotte score, INR international normalized ratio, ME
P<0.05 are reported as bold numbers.is very difficult, due to the different criteria used for the
evaluation of tumor response, TACE procedure, the select-
ivity of technique and the expertise of the radiological
center. This fact led to the investigation of the overall sur-
vival and clinical determinants of survival in patients with
a single nodule who represent approximately half (45%) of
the total cohort of patients who underwent a first
TACE cycle in our Interventional Radiology Unit (156/
344) (Figure 1). This number is fully comparable to a very
large Japanese series in which patients with single tumors








0 – 10.67) 1.85 (0.30 – 13.94) <0.001
0 – 5.00) 3.50 (2.10 – 4.50) <0.001












0 – 1.97) 1.33 (1.00 – 2.00) 0.003
– 24) 12 (7 –24) <0.001
LD Model for end stage liver disease.
Figure 2 Impact of TACE on laboratory tests one day after the procedure. (A) Modification of serum albumin (P < 0.001); (B) modification of
serum bilirubin (P < 0.001); (C) modification of serum INR (P = 0.003); (D) modification of serum creatinine (P = 0.823); (E) modification of MELD
score (P < 0.001).
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patients routinely undergoing TACE, including 35-50% of
patients with single tumors, even those <5 cm. Further-
more, the vast majority of the studies investigating the ef-
ficacy of TACE excluded patients with advanced liver
disease, PVT and impaired PS; therefore, there was also
no evidence of the impact of TACE in those categories of
patients [20]. The allocation policy and the impact of
TACE in patients with impaired liver function (namely
CPT-B patients) has already been described [21] and, in
the present study, the aim was to evaluate the impact of
bland PVT and slight impairment of PS on overall survival
after TACE.The median overall survival of the entire patient popu-
lation, after the exclusion of patients who underwent LT
who were generally long term survivors, was 36.0 months
with 1-, 3- and 5-years survival rates of 85%, 50% and
26%, respectively. These data are slightly lower than
those observed in a large Japanese series [5] reporting
1-, 3- and 5-years survival rates of 91%, 66% and 53%,
respectively in patients treated with TACE for a single
nodule of HCC (even though no information regarding
possible subsequent LT was reported). As expected,
when comparing these results with those reported in
the metanalysis of Llovet et al. (median survival of
20 months in patients who underwent TACE) in which
Table 5 Univariate survival analysis





Male 84 45 29 26.0 (16.7 – 35.3)
0.975
Female 88 63 20 41.0 (34.9 – 47.1)
Age, yr
<64 80 35 26 24.0 (21.5 – 26.5)
0.453
≥64 88 59 26 40.0 (36.2 – 43.8)
Cause of disease
Alcohol 81 28 21 24.0 (22.5 – 25.5)
0.081
Non alcohol 86 56 27 40.0 (33.0 – 47.0)
TACE selectivity
Lobar 87 58 58 44.0 (0 –104.8)
0.823Selective 87 51 29 36.0 (25.8 – 46.2)
Superselective 82 49 27 26.0 (10.2 – 41.8)
Milan criteria
Within (≤5.0 cm) 90 54 28 37.0 (30.2 – 43.8)
0.003
Beyond (>5.0 cm) 46 18 10 6.0 (0 – 17.3)
Portal vein thrombosis
Absent 86 50 24 36.0 (24.0 – 48.0)
0.876
Bland thrombosis 78 52 39 36.0 (4.6 – 67.4)
AFP, ng/mL
<14.5 89 58 39 41.0 (23.0 – 59.0)
0.052
≥14.5 79 43 22 25.0 (19.5 – 30.5)
Ascites
Absent 92 55 28 37.0 (29.0 – 45.0)
0.013
Present 57 32 16 15.0 (3.0 – 27.0)
Serum total bilirubin, mg/dL
<1.34 92 62 31 41.0 (36.6 – 45.4)
0.026
≥1.34 74 32 18 23.0 (18.1 – 27.9)
Serum albumin, g/dL
<3.60 81 40 20 24.0 (18.3 – 29.6)
0.340
≥3.60 87 55 29 40.0 (32.4 – 47.6)
Serum INR
<1.28 89 58 27 40.0 (34.5 – 45.5)
0.211
≥1.28 80 40 23 25.0 (18.8 – 31.2)
Hepatic function
CPT-A 93 60 26 40.0 (36.1 – 43.9)
0.075
CPT-B 83 47 22 21.0 (15.3 – 26.7)
Hepatic function. Pts Milan in patients
CPT-A 97 60 31 41.0 (37.2 – 44.8)
0.053
CPT-B 74 35 22 21.0 (14.3 – 27.7)
Performance status
0 92 61 34 36.0 (24.7 – 47.3)
0.080
1 78 41 18 28.0 (11.2 – 44.7)
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Table 5 Univariate survival analysis (Continued)
PS. Patients Milan In
0 91 55 31 41.0 (31.5 – 50.5)
0.029
1 83 50 0 28.0 (11.2 – 44.8)
BCLC stage
0 – A 91 55 31 41.0 (31.5 – 50.5)
0.002B 46 18 10 6.0 (0 – 17.3)
C 83 47 0 28.0 (11.2 – 44.8)
MELD score
< 11 92 61 34 41.0 (27.0 – 55.0)
0.060
≥ 11 78 41 18 25.0 (21.5 – 28.5)
Child-Pugh increase post-TACE
Absent 92 60 35 41.0 (33.6 – 48.3)
0.003
≥ 1 point 83 35 14 22.0 (10.3 – 33.6)
MELD increase post-TACE
Absent 94 39 44 44.0 (24.5 – 63.4)
0.003
≥ 1 point 80 43 17 25.0 (17.9 – 32.0)
Tumor response
CR 92 54 30 37.0 (25.4 – 48.6)
0.048
Non–CR 72 45 17 28.0 (17.8 – 38.2)
Recurrence
Absent 88 57 57 36.0 (12.1 – 59.9)
0.817
Present 94 72 55 40.0 (26.9 – 53.1)
Recurrence type
Local 95 63 32 42.0 (31.4 – 52.6)
0.312Distant intrahepatic 100 53 39 44.0 (9.5 – 78.5)
Local + distant intrahepatic 82 45 11 31.0 (12.1 – 49.9)
Patients submitted to liver transplant (LT) were excluded from the analysis (34 patients). The assessment of tumor response was considered at 1 month after
TACE. In the analysis of survival according to tumor response also patients not evaluable were excluded from the analysis.
Abbreviations: HCV hepatitis C virus, TACE transarterial chemoembolization, AFP Alpha-fetoprotein, INR international normalized ratio, CPT Child-Pugh-Turcotte
score, BCLC Barcelona Clinic Liver Cancer, MELD Model for end stage liver disease, CR complete response, PR partial response, PD progressive disease, PS= Performance
Statsus, BCLC Barcelona Clinic Liver Cancer.
P<0.05 are reported as bold numbers.
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http://www.biomedcentral.com/1471-2407/14/601the vast majority of patients had multinodular HCC [15],
the median overall survival was considerably higher des-
pite the large presence of CPT-B patients in our series. On
the basis of survival analysis, TACE treatment indeed rep-
resents a valid therapeutic option for patients with single
HCC who are not eligible for curative treatment, as has
also been shown by recent series of BCLC-A patients from
Barcelona and from Pisa [17,22]. Such data also supported
the use of the stage migration policy from the early to the
intermediate HCC stage.
When assessing the clinical predictors of survival,
tumor diameter >3 cm, and particularly >5 cm (beyond
the MC), lack of complete radiological tumor response,
AFP ≥14.5 ng/mL, the presence of ascites before TACE
and a MELD increase ≥1 point the day after TACE were
found to be independently associated with shorter survival
at multivariate analysis. These data are in agreement withthe fact that life expectancy depends not only upon tumor
treatment efficacy, but also on the underlying severity of
liver disease and patients with worsening hepatic function
after TACE; with a MELD score increase ≥1 point, they
are at risk of liver failure.
The presence of bland PVT in patients with HCC repre-
sents a challenging therapeutic issue. In recent decades,
some authors [23] have considered the presence of PVT
to be a contraindication for TACE due to the risk of liver
function deterioration and hepatic infarct [24] but patients
with PVT may not present technical and safety contrain-
dications to TACE if a selective/superselective procedure
is performed [20,25]. In fact, more recent studies have
demonstrated that TACE could be a safe treatment option
for HCC patients with PV occlusion especially when
performed in a selective manner [26], and that TACE
could have a survival benefit over conservative treatment
BCLC 0 - A
BCLC -B
BCLC -C
Figure 3 Overall survival according to BCLC tumor stage.
Table 6 Liver function parameters of patients with tumor burden within Milan criteria (n = 135) on the basis of
performance status
Variable PS-0 (n = 120) PS-1 (n = 15) P
Ascites, n (%) 1.000
Absent 98 (82) 12 (80)
Present 22 (18) 3 (20)
Encephalopathy, n (%) 0.300
Absent 118 (98) 14 (93)
Slight 2 (2) 1 (7)
Serum total bilirubin, median (mg/dL) (range) 1.39 (0.30 – 10.67) 1.23 (0.53 – 7.72) 0.817
Serum albumin, median (g/dL) (range) 3.60 (2.40 – 5.00) 3.60 (2.80 – 4.90) 0.596
Serum INR, median (range) 1.28 (1.00 – 1.97) 1.23 (1 – 1.86) 0.535
Serum creatinine, median (range) 0.92 (0.50 – 1.73) 0.78 (0.65 – 1.66) 0.115
Hepatic function, n (%) 0.784
CPT-A 74 (62) 10 (67)
CPT-B 46 (38) 5 (33)
Hepatic function, n (%) 0.655
CPT-A5 54 (45) 6 (40)
CPT-A6 20 (17) 4 (27)
CPT-B7 22 (18) 1 (7)
CPT-B8 19 (16) 2 (13)
CPT-B9 5 (4) 2 n
Abbreviations: CPT Child-Pugh-Turcotte score, INR international normalized ratio.
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http://www.biomedcentral.com/1471-2407/14/601[27,28]. In our Hospital, patients with bland thrombosis
are candidates for TACE if they have preserved liver func-
tion, limited tumor burden, contraindications to other
treatment and a selective approach is feasible. Interest-
ingly, despite the limited number of patients with bland
PVT (n = 17) who underwent TACE, our results showed
that the presence of bland PVT, either lobar or segmental,
has no negative impact on overall survival when TACE is
performed with a selective or superselective approach.
The BCLC staging system includes the ECOG PS [12]
evaluation regarding the assessment of tumor stage. In
patients with HCC, the classic determination of PS is
not able to differentiate between cancer- or cirrhosis-
related symptoms [16] and the subjective assessment of
“how the patient feels” can be related to cirrhosis as
well as to cancer. In our study population, 15 patients
with PS-1 were formally classified to be in the advanced
stage (BCLC-C) (Table 2) but, since the tumor diameter
was ≤5 cm, the likelihood of having cancer-related
symptoms could be considered very low. Accordingly,
these patients in BCLC-C had a significant and theoret-
ically paradoxical better survival (28 months) than pa-
tients in the BCLC-B stage (6 months), as all the latter
had large tumors (diameter >5 cm) (Tables 2, 5). It
could be speculated that, in case of symptoms of uncer-
tain tumor relation, the tumor burden should be consid-
ered the driving force for treatment allocation. On the
other hand, considering patients with the same tumor
burden (within the MC), PS-1, and consequently the same
liver function, this certainly impacts survival so that
BCLC-C patients (PS-1) had significantly worse survival
with respect to BCLC 0-A patients (PS-0) (Figure 3).
To the best of our knowledge, the only data on tumor
radiological response of conventional TACE in patients
with single unresectable HCC is that of Malagari et al.
[18]. Our study showed notably higher objective response
rates (CR + PR) of 90% vs. 59.6% and superior rates of CR
(64%) and PR (26%) (Table 3) as compared to the 4.8% CR
and 54.8% PR reported by Malagari. Our data appeared
consistent with those reporting per-nodule TACE efficacy
(mimicking patients with a single nodule) [29] where simi-
lar CR and PR rates were reported (64% and 36%, respec-
tively) and tumor diameter ≤5 cm was again found to be a
statistical predictor of complete response [29].
We acknowledge that the response rate in our study
might be overestimated since the assessment of radio-
logical response was usually made with CT, which may
underestimate the residual tumor due to the interference
of Lipiodol [13]. The availability of MRI was not sufficient
to offer this technique as a standard procedure after TACE
to all patients. Nevertheless, our data are of current
interest since, despite the introduction of TACE using
drug-eluting beads [30,31], clinical trials comparing
TACE with drug-eluting beads and conventional TACEdid not show significant differences in tumor response
and overall survival [19,32] and, nowadays, conventional
TACE is still for the most part used.
A number of studies have demonstrated that the repe-
tition of TACE increases tumor response and prolongs
survival [16], but it is necessary to select the best TACE
candidates who could benefit from treatment and even-
tually subsequent cancer retreatment in order to avoid
overtreatment and detrimental effects on liver function.
The issue of proper patient selection for retreatment
after TACE has become more stringent in recent years
due to the availability of alternative treatments such as
sorafenib [33], and radioembolization [24]. To this end,
the worsening of laboratory tests 24 hours after treat-
ment was evaluated and a significant modification in
serum albumin, bilirubin, the INR and the MELD score
after TACE treatment was documented (Figure 2). As
expected, it was also found that patients with a CPT score
increase ≥1 point were more likely to undergo a single
TACE cycle vs. multiple cycles (70% vs. 30%, P = 0.006)
Furthermore, both a CPT and a MELD score ≥1 point in-
crease were found to be associated with a significantly
worse prognosis (Table 4). Such findings do not affect the
initial choice of recommending TACE, but seem to alert
clinicians to consider the risk that patients will be no more
candidate for future repeated TACE in case of early CPT
score worsening after the procedure, deserving an even
more careful assessment of treatment strategy.
Conclusion
In conclusion, our results showed TACE to be an effect-
ive curative treatment in patients with a single nodule of
HCC who were not eligible for curative treatment, sup-
porting the strategy of stage migration for early single
HCC. Bland PVT has no major impact on survival and a
slight impairment of PS (PS-1) most likely attributable
to cirrhosis in patients with a tumor burden within the
Milan criteria should not preclude the use of TACE.
This confirmed the fundamental role of individual cli-
nical judgment in the treatment of HCC.Competing interests
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